The April 20 report, the latest performance analysis commissioned by the Phoenix-based Flinn Foundation and presented by TEConomy Partners, shows record highs in bioscience jobs, wages, venture capital, National Institutes of Health research funding, and university research and development.Continue reading
TUCSON, AZ / ACCESSWIRE / April 20, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the signing of a license agreement with the LeaderMed Health Group Limited (“LeaderMed”). The License Agreement provides LeaderMed with Asia-Pacific regional rights to further develop, manufacture, and commercialize the eNAMPT-neutralizing mAb, ALT-100 platform technology. The terms of the agreement have not been publicly disclosed but involve customary upfront fees, achievement milestones, and royalties that coincide with commercial sales.Continue reading
The first treatment for West Nile virus. A robotic device for children with cerebral palsy. A universal antivenom for snake bites. These goals emerge from three of the 10 translational research projects receiving funding from the Flinn Foundation in 2022 as part of a program to advance new products and services to improve patient care.Continue reading
TUCSON, Ariz., April 14, 2022 – Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its Critical Path for Sickle Cell Disease (CP-SCD) Consortium.Continue reading
TUCSON, Ariz.– The University of Arizona Center for Innovation (UACI) held a grand opening yesterday to celebrate its new startup incubator at Biosphere 2, which supports renewable energy and sustainable tech startups.
PHOENIX, March 31, 2022 /PRNewswire/ — Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo®. Equus Innovations is also the manufacturer of the highly successful RenoVō® equine allograft, distributed by Equine Amnio Solutions, LLC (EAS).
TUCSON, Ariz., – April 11, 2022 – Avery Therapeutics, Inc. (Avery), a privately held, pre-clinical stage therapeutics company, today announced a publication in the peer-reviewed scientific journal, Nature Scientific Reports, outlining a novel technique in cardiac magnetic resonance imaging (CMR) data acquisition utilizing smart-signal gradient recalled echo (GRE)-based array sequences, entitled, “Free-breathing gradient recalled echo-based CMR in a swine heart failure model,” (Morris, el al. (2022). Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-07611-8).
Global Center for Technology Transfer will focus on research, education
The University of Arizona College of Medicine-Phoenix will receive $5.5 million over five years from the Flinn Foundation to support translational research in cardiovascular diseases, neurosciences, and serious mental illnesses.Continue reading
On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease. In its official statement, the Biotechnology Innovation Organization (BIO) shares why the CMS Decision is an enormous setback for Alzheimer’s patients and a dangerous infringement on FDA’s Scientific Autonomy.